Pharma


  • Image attribution tooltip
    Novartis
    Image attribution tooltip

    Novartis radiopharmaceutical drug succeeds in first-line gut cancer study

    Novartis has made a large investment in targeted radiotherapies, sparking competition from fellow pharma companies and young biotechs.

    By Sept. 25, 2023
  • Vials of Eisai and Biogen's new Alzheimer's drug Leqembi
    Image attribution tooltip
    Courtesy of Eisai
    Image attribution tooltip
    New Alzheimer's drugs

    Eisai’s Alzheimer’s drug Leqembi approved in Japan

    Eisai and Biogen’s anti-amyloid drug is still undergoing regulatory reviews in the EU, U.K. and elsewhere.

    By Sept. 25, 2023
  • Single strand ribonucleic acid, RNA research Explore the Trendline
    Image attribution tooltip
    luismmolina via Getty Images
    Image attribution tooltip
    Trendline

    The expanding world of RNA therapies

    Vaccines from BioNTech and Moderna proved the power of messenger RNA in medicine. A growing field of RNA-targeting therapies is advancing alongside them.

    By BioPharma Dive staff
  • Doctors working in lab
    Image attribution tooltip

    Anthony Musmanno

    Image attribution tooltip
    Sponsored by Viatris

    Driving innovation to benefit people living with MS

    A holistic approach to R&D is key to support MS patients throughout their treatment journey.

    By Pat Vallano, Ph.D., Head of Innovative Programs, R&D, Viatris • Sept. 25, 2023
  • Image attribution tooltip
    Jacob Bell / BioPharma Dive
    Image attribution tooltip

    AstraZeneca and Daiichi’s next cancer medicine scores in breast tumors

    Results show that the medicine helped patients who progressed on earlier-line treatments live longer than those receiving chemotherapy without their disease getting worse, according to a Friday announcement.

    By Sept. 22, 2023
  • Exterior of FDA headquarters
    Image attribution tooltip
    Courtesy of U.S. Food and Drug Administration
    Image attribution tooltip

    Alvotech gets new FDA review for Humira biosimilar

    The regulator has twice rejected Alvotech’s copycat drug due to manufacturing issues with a plant in Europe.

    By Sept. 20, 2023
  • Congressman Garcia gestures to a cardboard meme of two identical Spiderman characters pointing at one another.
    Image attribution tooltip
    Rebecca Pifer/BioPharma Dive
    Image attribution tooltip

    PBMs, PhRMA trade blame over drug costs in House hearing

    Pharmacy benefit manager lobby PCMA and drugmaker lobby PhRMA pointed fingers over problems in the prescription supply chain during the House committee's second hearing on the PBM industry.

    By Rebecca Pifer • Sept. 19, 2023
  • Image attribution tooltip
    Jonathan Gardner / BioPharma Dive
    Image attribution tooltip

    Novartis cancels Beigene partnership as cancer drug gains EU approval

    The terminated deal leaves Novartis without a PD-1 inhibitor nine years after Merck’s Keytruda won its first approval.

    By Sept. 19, 2023
  • FTC
    Image attribution tooltip
    Carol Highsmith. (2005). "Apex Bldg." [Photo]. Retrieved from Wikimedia Commons.
    Image attribution tooltip

    FTC takes aim at pharma patent tactics used to block generics

    The antitrust regulator is examining what it describes as abuse of the FDA “Orange Book” — another step in its scrutiny of pharma business practices.

    By Sept. 15, 2023
  • Image attribution tooltip
    Sarah Silbiger via Getty Images
    Image attribution tooltip

    FDA approves updated COVID boosters from Pfizer, Moderna

    Pfizer and Moderna, which have seen slowing demand for their coronavirus vaccines, expect their reformulated shots will soon be available in the U.S.

    By Sept. 11, 2023
  • Image attribution tooltip
    Novartis
    Image attribution tooltip

    Novartis stops work on gene therapy acquired in Gyroscope deal

    The decision follows a review by a trial monitoring committee, which concluded data for the geographic atrophy treatment didn't support further development.

    By Sept. 11, 2023
  • Roche Pharmaceutical Group's office building in Shanghai, China
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    Manufacturing delays under-the-skin Tecentriq shot in US

    Roche says it won’t be able to launch the subcutaneous version of the drug until 2024 as it works with the FDA on manufacturing updates.

    By Sept. 8, 2023
  • The Moderna headquarters is seen on November 30, 2020 in Cambridge, Massachusetts.
    Image attribution tooltip
    Maddie Meyer via Getty Images
    Image attribution tooltip

    Moderna says updated COVID shot likely to protect against worrisome variant

    The findings add to early evidence showing a heavily mutated variant called BA.2.86, which is growing in prevalence, may not be as evasive as scientists once feared.

    By Sept. 6, 2023
  • Illustration of lung cancer
    Image attribution tooltip
    SciePro via Getty Images
    Image attribution tooltip

    Roche claims study success for targeted drug in early lung cancer

    The Swiss pharma said, without details, that it observed “unprecedented” results that could make Alecensa the first treatment specifically available after surgery for ALK-positive lung tumors.

    By Sept. 1, 2023
  • Sanofi appoints a venture investor to R&D head as executive team expands

    Houman Ashrafian, currently a scientific advisor at SV Health Investors, will fill the role left by John Reed, who oversaw the transformation of research and development during his five years at Sanofi.

    By Aug. 31, 2023
  • A skyline of a smart city with several glowing light trails running through it.
    Image attribution tooltip
    Permission granted by ZS
    Image attribution tooltip
    Sponsored by ZS

    The intelligent content ecosystem is here. Is your organization ready?

    Is pharma up to the challenge of delivering the personalized and contextual experiences doctors have come to expect? Too often, the answer is no.

    By Saby Mitra, Global Digital Customer Experience Practice Leader at ZS • Aug. 28, 2023
  • A medical Illustration showing lung cancer or bronchial carcinoma.
    Image attribution tooltip
    Mohammed Haneefa Nizamudeen via Getty Images
    Image attribution tooltip

    Roche’s surprise study results spur new optimism for TIGIT drugs

    Data inadvertently published from a closely watched lung cancer study suggest a drug blocking the protein TIGIT may help extend survival, a finding that boosted shares of other developers. 

    By Aug. 23, 2023
  • Phil Inc header image abstract
    Image attribution tooltip
    Permission granted by Phil Inc
    Image attribution tooltip
    Sponsored by Phil

    8 key components of a telemedicine program that delivers an exceptional patient experience

    Discover how to accelerate patient access and commercial success through a best-in-class telemedicine program.

    Aug. 21, 2023
  • A pharmacist prepares to administer COVID-19 vaccine booster shots on September 09, 2022 in Chicago, Illinois.
    Image attribution tooltip
    Scott Olson via Getty Images
    Image attribution tooltip

    Moderna builds case for updated COVID shot ahead of latest booster push

    But the demand for booster shots ahead of an expected surge of infections this fall remains an unanswered question weighing heavily on Moderna’s future outlook. 

    By Aug. 18, 2023
  • Merck sign
    Image attribution tooltip
    Marko Georgiev / Stringer via Getty Images
    Image attribution tooltip

    Merck says drug acquired in $1B buyout scores in large kidney cancer study

    The treatment, which Merck picked up through a 2019 acquisition of Peloton Therapeutics, helped delay disease progression in patients with advanced renal cell carcinoma. 

    By Aug. 18, 2023
  • Obesity drugs

    Boehringer moves Wegovy competitor into late-stage testing

    The German pharmaceutical company is launching three Phase 3 trials of an obesity drug called survodutide, which like Wegovy targets the GLP-1 receptor

    By Aug. 17, 2023
  • Amazon Pharmacy
    Image attribution tooltip
    Courtesy of Amazon
    Image attribution tooltip

    Amazon Pharmacy expands insulin manufacturer coupons

    The new coupons include some of the most commonly prescribed diabetes drugs from Eli Lilly, Novo Nordisk and Sanofi.

    By Rebecca Pifer • Aug. 17, 2023
  • A logo of Gilead Sciences
    Image attribution tooltip
    Permission granted by Gilead Sciences
    Image attribution tooltip

    Gilead antibody drug shows signs of potential in early lung cancer

    A combination of Trodelvy and Merck’s Keytruda appears active against lung tumors, but has a high bar to clear and faces competition from AstraZeneca and Daiichi Sankyo.

    By Aug. 17, 2023
  • Rep. Adam Smith sits at a podium with blue curtain behind.
    Image attribution tooltip
    Chip Somodevilla / Staff via Getty Images
    Image attribution tooltip
    Q&A

    A leading Democrat reveals how his mental health struggles shape his policy approach

    Seattle Congressman Adam Smith's journey with anxiety and chronic health has influenced his perspective on healthcare and pharmaceutical policy.

    By Karissa Waddick • Aug. 17, 2023
  • Image attribution tooltip
    Spencer Platt via Getty Images
    Image attribution tooltip

    FDA approves bispecific drug from Pfizer for multiple myeloma

    Elrexfio is the third bispecific antibody cleared to treat the cancer, and will compete with other therapies that target the “BCMA” protein on myeloma cells.

    By Aug. 14, 2023
  • FDA delays decision on Valneva’s chikungunya vaccine

    The agency needs more time to settle with Valneva the design of a post-marketing study for the shot, which could become the first preventive therapy for chikungunya available in the U.S.

    By Aug. 14, 2023